Genetically modified human stem cell expressing a mutant human cytochrome P450 2B6 protein and its use in cancer treatment
Genetically modified stem cells expressing a mutant cytochrome P450 2B6 protein and NADPH-cytochrome P450 reductase protein address the limitations of current hepatocellular carcinoma treatments by inducing immunological tumor cell death and preventing recurrences, offering a controlled and sustained therapeutic approach with reduced side effects.
Patent Information
- Application Number
- FR2019011386
- Authority / Receiving Office
- FR · FR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2019-10-14
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2039-10-14
AI Technical Summary
Current treatments for hepatocellular carcinoma, such as Sorafenib, Regorafenib, and Nivolumab, have limited effectiveness and significant adverse effects, leading to poor patient compliance and suboptimal results, while there is a need for new therapies that provide controlled and sustained cancer treatment with reduced side effects.
Development of genetically modified human stem cells, such as mesenchymal stem cells, induced pluripotent stem cells, and induced mesenchymal stem cells, engineered to express a mutant human cytochrome P450 2B6 protein and NADPH-cytochrome P450 reductase protein, capable of metabolizing cyclophosphamide and inducing immunological tumor cell death.
The genetically modified stem cells effectively eradicate solid tumors, including hepatocellular carcinomas, by triggering a strong anti-tumor immune response and preventing recurrences and metastases, while maintaining cell morphology and doubling time.
Abstract
Description
Title of the invention: Genetically modified human stem cell expressing a mutant human cytochrome P450 2B6 protein and its use in the treatment of cancer Technical field
[0001] The present invention relates to a genetically modified human stem cell, wherein said human stem cell comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof and an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, operably linked to a promoter, said exogenous nucleic acid having been integrated into one of the safe harbor genes of said human stem cell. The invention also relates to the use of said cell for the treatment of cancer, in particular solid tumors, and in particular hepatocellular carcinomas. Prior art
[0002] Liver cancers represent more than 841,080 new cases worldwide per year, 90% of which are hepatocellular carcinomas. Hepatocellular carcinoma is the third leading cause of cancer mortality worldwide. Chronic infection with hepatitis C (HCV) and hepatitis B (HBV) viruses or alcoholic cirrhosis are the main causes of hepatocellular carcinoma. Furthermore, over the last 10 years, the emergence of non-alcoholic steatohepatitis (NASH) linked to the increase in obesity, pre-diabetic conditions and type 2 diabetes is an emerging cause of hepatocellular carcinoma. Treatment of hepatocellular carcinoma is essential, otherwise it will become fatal. Given the increase in patients with non-alcoholic steatohepatitis, it is highly likely that the number of patients with hepatocellular carcinoma will increase in the coming years.Spontaneous survival of patients with hepatocellular carcinoma does not exceed 15 months. The BCLC (Barcelona Cancer Liver Center) classification distinguishes 5 types of clinical situation.
[0003] Stages 0 and A (early) (15% of patients) define patients with early diagnosed disease, in good general condition and with hepatocellular carcinoma less than 3cm. These patients are eligible for curative treatments only, which are tumor resection surgery and liver transplantation. 5-year survival is 60%.
[0004] Stage B (intermediate) concerns patients whose general condition is preserved but presenting one or more hepatocellular carcinoma(s) larger than 3 cm, without invasion of the portal trunk or metastases. These patients can benefit from hepatic chemoembolization with doxorubicin. The median survival of these patients is 20 months.
[0005] Stage C (advanced) defines a patient with hepatocarcinoma with portal invasion, lymph node and pulmonary metastases associated with moderate deterioration of their general condition.
[0006] The standard treatment at this advanced stage is Sorafenib, an orally administered antiangiogenic multikinase inhibitor marketed under the name Nexavar® by Onyx / Bayer. In these patients, the median survival is 11 months. Other second-line treatments have recently been approved. These are Regorafenib (kinase inhibitor) marketed under the name Stivarga® by Bayer and Nivolumab (anti-PD1 antibody) marketed under the name Opdivo®, by BMS. All these treatments have limited efficacy and are responsible for major adverse effects (diarrhea, weight loss, hand-foot syndrome and hypophosphatemia, high blood pressure) often causing poor treatment compliance leading to suboptimal results.
[0007] Stage D concerns patients who have reached the palliative stage for which only supportive care can be offered.
[0008] Thus, there is a need for new effective forms of cancer treatment, in particular solid tumors and in particular hepatocellular carcinomas, in particular treatments which can provide controlled and sustained therapy, alone or in combination with other therapies, while improving the patient's quality of life and reducing the side effects linked to the treatment.
[0009] In order to prevent and / or treat cancer and / or associated metastases, and in particular solid tumors, and in particular hepatocellular carcinoma and / or associated metastases, the inventors have developed a novel genetically modified human stem cell capable of metabolizing cyclophosphamide and inducing the immunological death of tumor cells by provoking a strong anti-tumor immune response. Summary of the invention
[0010] Thus, the present invention relates to a genetically modified human stem cell, wherein said human stem cell comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof, an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, operably linked to a protein ... tional to a promoter, said exogenous nucleic acid having been integrated into a safe harbor gene of said human stem cell.
[0011] Advantageously, the human stem cell is chosen from mesenchymal stem cells (hMSC), induced pluripotent stem cells (iPSC) and induced mesenchymal stem cells (iMSC).
[0012] Advantageously, the promoter used is a constitutive promoter, preferably the EF1-a promoter. Advantageously, the exogenous nucleic acid further comprises a selection marker gene.
[0013] The present invention also relates to a method for obtaining the genetically modified human stem cell, said human stem cell was obtained by retroviral transduction with a viral vector comprising the exogenous nucleic acid.
[0014] The present invention also relates to the genetically modified human stem cell for its use as a medicament and its formulation in a form suitable for its administration by trans-arterial route.
[0015] The present invention also relates to a method for selecting genetically modified stem cells comprising the steps of: a) transduction of human stem cells with a viral vector comprising the exogenous nucleic acid, b) culturing human stem cells in a predefined culture medium, c) selecting genetically modified human stem cells expressing the selection marker gene on their membrane surface.
[0016] The present invention further relates to a pharmaceutical composition comprising the genetically modified human stem cell as active ingredient and at least one pharmaceutically acceptable excipient and optionally at least one second active ingredient, in particular an anti-cancer agent, said pharmaceutical composition being in a form suitable for its administration by trans-arterial route.
[0017] The invention also relates to a genetically modified human stem cell or pharmaceutical composition for its use in the prevention and / or treatment of cancer and / or cancer recurrences and / or associated metastases, preferably solid tumors, preferably hepatocellular carcinomas and / or associated metastases. Detailed description of the invention
[0018] The present invention therefore relates to a genetically modified human stem cell, in which said human stem cell comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof, an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, operably linked to a promoter, said exogenous nucleic acid having been integrated into a safe harbor gene of said human stem cell.
[0019] The inventors have surprisingly shown that the integration of the exogenous nucleic acid into a safe harbor gene is essential for the genetically modified human stem cell to be able to metabolize cyclophosphamide (CPA) and thus induce the immunological death of tumor cells. In addition, this integration of the exogenous nucleic acid into a safe harbor gene allows the genetically modified human stem cell to maintain its morphology and doubling time. Furthermore, the inventors have shown that a single copy of the exogenous nucleic acid is integrated into a safe harbor gene. The inventors have also shown that the use of genetically modified human stem cells according to the invention allows the complete eradication of solid tumors as well as protection by vaccination effect against recurrences and metastases.
[0020] In a particular embodiment of the invention, the human stem cell is chosen from mesenchymal stem cells (hMSC), induced pluripotent stem cells (iPSC) and induced mesenchymal stem cells (iMSC).
[0021] For the purposes of the present invention, the term "mesenchymal stem cells" or "hMSC" or "human mesenchymal stem cells" refers to multipotent stem cells capable of differentiating, in particular, into osteoblasts, chondrocytes, myocytes and adipocytes. Mesenchymal stem cells are found in the mesenchyme, the part of the embryonic mesoderm consisting of spindle or stellate cells, not loosely packed. As used herein, mesenchymal stem cells include, without limitation, CD34-negative stem cells. In one embodiment of the invention, the human mesenchymal stem cells are isolated from adipose tissue and / or bone marrow.
[0022] For the purposes of the present invention, the term "induced pluripotent stem cells" or "iPSCs" or "human induced pluripotent stem cells" means a type of pluripotent stem cell similar to an embryonic stem cell but which is created when somatic cells (e.g., adult) are reprogrammed to enter a state similar to that of an embryonic stem cell by maintaining the expression of factors important for maintaining the "pluripotency" of embryonic stem cells (also called ESCs or PSCs), i.e. their ability to be able to engage in different differentiation pathways. Such factors may include certain embryonic genes (such as the OCT4, SOX2, and LF4 transgenes). As used herein, the term "pluripotent" refers to a cell or cell lineage capable of differentiating into any differentiated cell type, e.g., an ability to develop into all three germ layers of the organism's development, including endoderm, mesoderm, and ectoderm.
[0023] For the purposes of the present invention, the term “induced mesenchymal stem cells” or “iMSC” or “human induced mesenchymal stem cells” designates mesenchymal stem cells derived from induced pluripotent stem cells (iPSC).
[0024] In a particular embodiment of the invention, the human stem cell is a mesenchymal stem cell (hMSC). In another particular embodiment of the invention, the human stem cell is an induced pluripotent stem cell (iPSC). In another particular embodiment of the invention, the human stem cell is an induced mesenchymal stem cell (iMSC).)
[0025] For the purposes of the present invention, the term "exogenous nucleic acid" designates a nucleic acid not naturally present in the human stem cell according to the invention. The exogenous nucleic acid may be genomic DNA, cDNA, natural DNA or DNA obtained totally or partially by chemical synthesis. According to one embodiment of the invention, the exogenous nucleic acid is of therapeutic interest.
[0026] In a particularly advantageous embodiment of the invention, the exogenous nucleic acid comprises a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof, an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof.
[0027] In a particularly advantageous embodiment, the human cytochrome P450 2B6 protein is a mutant human cytochrome P450 2B6 protein, also called CYP2B6*, of SEQ ID No. 1 or a variant or fragment thereof, wherein said variant or fragment comprises residues 114V, 199M and 477W as represented in the amino acid sequence SEQ ID No. 1. Advantageously, said variant or fragment retains a biological activity of a protein having the amino acid sequence SEQ ID No. 1.
[0028] SEP ID No.l (CYP2B6*): MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPR-PLPLLGNLLQMDRRGLLKSFLRFREKYGDVFTVHLGPRPVVMLCGVEAIREAL VDKAEAFSGRGKIAMVDPFFRGYGVVFANGNRWKVLRRFSVTTMRDFGMGK RSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIICSIVFGKRFHYQDQEF LKMMNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQEINAYIGHSV EKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGTETT STTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQ RFSDLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDH FLDANGALKKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDI DLTPQECGWGKIPPTYQIRFLPR
[0029] The amino acid sequence of human cytochrome P450 2B6 type protein wild type (CYP2B6 WT) is represented by the sequence SEQ ID No.3.
[0030] SEP ID No.3 (CYP2B6 WT): MELSVLLFLALLTGLLLLLVQRHPNTH-DRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFREKYGDVFTVHLGPRPVVMLCG VEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNRWKVLRRFSVTTM RDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIICSIVFGKR FHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQEI NAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLS LFFAGTETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPY TEAVIYEIQRFSDLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEK PDAFNPDHFLDANGALKKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSM ASPVAPEDIDLTPQECGVGKIPPTYQIRFLPR
[0031] Advantageously, the mutant human cytochrome P450 2B6 protein (CYP2B6*) has an affinity for CPA more than 8 times higher than that of the wild-type protein (CYP2B6 WT), while retaining the same Vmax, in particular due to the substitutions II 14V, L199M and V477W as presented in SEQ ID No. 1. As described below, variants and fragments of the amino acid sequence SEQ ID No. 1 are encompassed within the scope of the invention. However, all mutant human cytochrome P450 2B6 proteins, variants and fragments of the invention as described herein retain Val at the position corresponding to residue 114 of the amino acid sequence SEQ ID No. 1, Met at the position corresponding to residue 199 of the amino acid sequence SEQ ID No. 1 and Trp at the position corresponding to residue 477 of the amino acid sequence SEQ ID No. 1.
[0032] The amino acid sequence of the wild-type NADPH-cytochrome P450 reductase protein (NADPH WT) is represented by the sequence SEQ ID No. 2. The variants and fragments of the NADPH-cytochrome P450 reductase protein of amino acid sequence of SEQ ID No. 2, described below, are also within the scope of the invention.
[0033] SEP ID No, 2 (NADPH WT): IQTLTSSVRESSFVEKMKKTGRNIIVFYGSQTG-TAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYG EGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEHFNAMGKYVDKR LEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEESSIRQ YELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQG TERHLMHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSL NNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELL RKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPRLQARYY SIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPAGENGGRAL VPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWLRQQGKEVGETL LYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHKVYVQHLLKQDR EHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVDYIKK LMTKGRYSLDVWS
[0034] Protein variants may be naturally occurring variants, such as splice variants, alleles, and isoforms, or they may be produced by recombinant means. Variations in the amino acid sequence may be introduced by substitution, deletion, or insertion of one or more codons in the nucleic acid sequence encoding the protein, resulting in a change in the amino acid sequence of the protein. Optionally, the variation may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids with any other amino acid. Additionally or alternatively, variation may be introduced by addition or deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids within the protein. Amino acid substitutions may be conservative or non-conservative.Preferably, the substitutions are conservative substitutions, in which one amino acid is substituted for another amino acid having similar structural and / or functional and / or chemical properties. Examples of conservative substitutions are listed below: . Ala (A) Val; Leu; Ile Arg(R) Lys; Gin; Asn Asn (N) Gin; His; Lys Asp (D) Glu Cys (C) Ser Gin (Q) Asn Glu (E) Asp Gly (G) Pro; Ala; ala His (H) Asn; Gin; Lys; Arg; Island (1) Leu; Val; Met; To the; norleucine Leu Leu (L) norleucine; Ile; Met; Ala; Phe Lys (K)Arg; Gin; Asn Met (M) Leu; Phe; Phe Island (F) Leu; Val; Island; To the; Tyr Pro (P) Ala Ser (S) Thr Thr (T) Ser Trp (W) Tyr; Phe; Tyr (Y) Trp; Phe; Thr; Ser; Val (V) Island; Leu; Met; Phe; To the; norleucine.
[0035] Protein variants may include proteins that have at least about 80% amino acid sequence identity with a polypeptide sequence described herein. Advantageously, a protein variant will have at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% amino acid sequence identity with a full-length amino acid sequence or a fragment of an amino acid sequence of SEQ ID No. 1 and / or SEQ ID No. 2.
[0036] Amino acid sequence identity is defined as the percentage of amino acid residues in the variant sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percentage of sequence identity, and not considering conservative substitutions as part of the sequence identity. Sequence identity may be determined over the entire length of the variant sequence, over the entire length of the reference sequence, or over both. Methods for sequence alignment and determining sequence identity are well known in the art, for example, using publicly available software such as BioPerl, BLAST, BLAST-2, CS-BLAST, FASTA, ALIGN, ALIGN-2, LALIGN, Jaligner, matcher, or Megalign (DNASTAR) software.
[0037] Fragments of the proteins and protein variants described herein are also encompassed by the invention. Such fragments may be truncated at the N-terminus or the C-terminus, or may lack internal amino acid residues outside the N-terminus and C-terminus, for example, relative to a full-length protein. Some fragments lack amino acid residues that are not essential for enzymatic activity. Advantageously, said fragments are at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 150, 200, 250, 300, 350, 400, 450, 500 or more amino acids in length.
[0038] Preferred fragments of the proteins described herein comprise all or part of the active site. Preferred fragments of mutant human cytochrome P450 2B6 protein (CYP2B6*) comprise or consist of amino acids 1 to 490 of the full-length sequence SEQ ID No. 1. Preferred fragments of NADPH-cy-tochrome P450 reductase protein comprise or consist of fragments comprising or consisting of amino acids 60 to 680 of the amino acid sequence SEQ ID No. 2.
[0039] The variants and fragments of the invention preferably retain a biological activity of the complete protein. The variants and fragments of the human cytochrome P450 2B6 protein advantageously have an oxidation activity of a substrate such as cyclophosphamide (CPA), or of another substrate, in particular by catalyzing the hydroxylation to 4-OH-CPA.
[0040] In a particularly advantageous embodiment, said variants and fragments have an affinity for cyclophosphamide (CPA) greater than that of the human cytochrome P450 2B6 protein of sequence SEQ ID No. 3, preferably at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 times that of the wild-type sequence.
[0041] In a particularly advantageous embodiment, said variants and fragments have an affinity for CPA identical, substantially identical or greater than that of the mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1. Methods for assaying said activity and this affinity are well known to those skilled in the art and are described in particular in Nguyen et al., Mol Pharmacol, 2008, 73: 1122-1133.
[0042] Variants and fragments of the NADPH-cytochrome P450 reductase protein preferably have cytochrome c reducing activity, preferably in an NADPH-dependent manner.
[0043] In a preferred embodiment, said variants and fragments have an activity identical to, substantially greater than or equal to, that of the full-length NADPH-cytochrome P450 reductase protein (SEQ ID No. 2). Methods for assaying this activity are well known to those skilled in the art and are described in particular in Yasukochi et al; Arch Biochem Biophys, 1980, 202: 491-498.
[0044] Those skilled in the art will be able to determine the amino acid residues that can be inserted, substituted, or deleted without adversely affecting the activity of the protein by using knowledge of the protein structure available in the art and publicly available molecular modeling techniques (see, for example, Nguyen et al. Mol Pharmacol 2008, 73: 1 122-1133). The permissible variation can be determined by systematically making amino acid insertions, deletions, or substitutions in the sequence and testing the resulting variants for activity exhibited relative to the wild-type protein.
[0045] For the purposes of the present invention, the term "fusion protein" means a chimeric protein created by joining two or more genes encoding distinct proteins or protein fragments, such as different protein domains, into a single reading frame encoding a single translated protein.
[0046] The fusion protein of the present invention preferably comprises: - a mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof, and - an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof as described above.
[0047] In a particularly advantageous embodiment, said fusion protein of sequence SEQ ID No.4 comprises: - residues 1 to 490 of the mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof and - residues 57 to 678 of the NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof.
[0048] SEP ID No.4 (protein de fusion) : MELSVLLFLALLTGLLLLLVQRHPNTH-DRLPPGPRPLPLLGNLLQMDRRRGLLKSFLRFREKYGDVFTVHLGPRPVVMLCG VEAIREALVDKAEAFSGRGKIAMVDPFFRGGYGVVFANGNRWKVLRRFSVTTM RDFGMGKRSVERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIICSIVFGKR FHYQDQEFLKMMNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQEI NAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLS LFFAGTETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPY TEAVIYEIQRFSDLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEK PDAFNPDHFLDANGALKKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSM ASPVAPEDIDLTPQECGWGKIPPTYQIRFLPRSSSTIQTLTSSVRESSFVEKMKKT GRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEID NALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEH FNAMGKYVDKRLEQLGAQRIFELGDDGNLEEDFITWREQFWPAVCEHFG VEATGEESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLA AVTTNRKLNQGTERHLMHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKI LGADLDVVMSLNNLDEESNKHPFPCPPTSYRTALTYYLDITNPPRTNVLYELA QYASEPSEQELLRKMASSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHL CELLPRLQARYYSIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWL RQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHK VYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAM EHAQAVDYIKKLMTKGRYSLDVWSRAEGRGSLLTCGDVEENPGPMLVRRGA RAGPRMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQE TTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTS VISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIK AEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAG AQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQ DVASHQSYSQKTLIALVTSGALLAVLGITGYFLMNRRSWSPTGERLELEP*.
[0049] The mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof may be upstream or downstream of the protein NADPH-cytochrome P450 reductase of SEQ ID No. 2 or a variant or fragment thereof. Preferably, the mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof is upstream of the NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof.
[0050] Where the context permits, the term "proteins of the invention", "the proteins disclosed herein", should be understood as encompassing said fusion proteins.
[0051] The proteins or protein fragments constituting the fusion protein may be separated by a linker peptide sequence or a spacer. The linker peptide sequence, also called a "linker" or the spacer, also called a "spacer", serves to separate the component proteins or protein fragments and to aid in the efficient folding and activity of the individual components. The linker peptide sequence or spacer may include an enzymatic cleavage site to allow the polypeptide components to be separated by enzymatic digestion. The linker peptide sequence or spacer may be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more amino acids. Preferably, the linker peptide sequence or spacer is less than 10, less than 9, less than 8, less than 7, less than 6 or less than 5 amino acids in length.Examples of linker or spacer peptide sequences for use in the fusion proteins of the present invention include (Ser)nThr, where "n" is an integer, preferably 1, 2, 3, 4, 5, 6, 7, 8 or 9. In a preferred embodiment, "n" is 5. In another preferred embodiment, "n" is 3.
[0052] For the purposes of the present invention, the term "safe harbor gene" or "safe harbor" designates a region of the genome where it is possible to integrate genetic material without disrupting the function, transcription and regulation of the native coding sequences, as well as the gene structure. A "safe harbor" allows sufficient expression of the exogenous nucleic acid without predisposing the human stem cell according to the invention to malignant transformation or altering its function.
[0053] In a particular embodiment of the invention, the exogenous nucleic acid is integrated into a safe harbor gene. Advantageously, the exogenous nucleic acid is integrated into the safe harbor gene chosen from: the AAVS1 site of chromosome 19, the CCR5 site of chromosome 3, the hROSA26 site of chromosome 3, the site 323 of chromosome 1, the site 325 of chromosome 8, the site 289 of chromosome 1, the site 227 of chromosome 1, the site 229 of chromosome 2, the site 253 of chromosome 2, the site 255 of chromosome 5, the site 257 of chromosome 7, the site 259 of chromosome 14, the site 261 of chromosome 17, the site 263 of chromosome X, the site 317 of chromosome 2, the site 303 of chromosome 2, the site 331 of chromosome 3, the site 283 of chromosome 4, the site 231 of chromosome 4, site 315 of chromosome 5, site 327 of chromosome 5, site 305 of chromosome 5, site 307 of chromosome 16, site 309 of chromosome 20, site 285 of chromosome 6, site 233 of chromosome 6, site 311 of chromosome 6, site 299 of chromosome 6, site 301 of chromosome 7, site 293 of chromosome 8, site 319 of chromosome 11, site 333 of chromosome 12, site 295 of chromosome 12, site 329 of chromosome 12, site 297 of chromosome 17, site 291 of chromosome 22, site 313 of chromosome X and site 321 of chromosome X.
[0054] In a particular embodiment of the invention, the promoter to which is operably linked the region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof, an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, is a constitutive promoter. Advantageously, the constitutive promoter may be chosen from the CMV promoter, the CBA promoter and the EF1-a promoter. Advantageously, the constitutive promoter is the EF1-a promoter.
[0055] In a particular embodiment of the invention, the exogenous nucleic acid further comprises a selection marker gene. For the purposes of the present invention, the term "selection marker gene" means a coding sequence for a selectable marker protein, which allows the selective retention of human stem cells having integrated the exogenous nucleic acid during the culture and propagation of the cells. Advantageously, the selection marker gene is the CD34 gene, advantageously the CD34 gene having undergone splicing, also called the spliced CD34 gene.
[0056] Advantageously, the selection marker gene is the spliced CD34 gene of sequence SEQ ID No. 5:
[0057] SEQ ID No. 5 (CD34 spliced selection marker gene): ATGCTGGTCCG- CAGGGGCGCGCGCGCAGGGCCCAGGATGCCGCGGGGCTGGACCGCGCTTT GCTTGCTGAGTTTGCTGCCTTCTGGGTTCATGAGTCTTGACAACAACGGTAC TGCTACCCCAGAGTTACCTACCCAGGGAACATTTTCAAATGTTTCTACAAA TGTATCCTACCAAGAAACTACAACACCTAGTACCCTTGGAAGTACCAGCCT GCACCCTGTGTCTCAACATGGCAATGAGGCCACAACAAACATCACAGAAA CGACAGTCAAATTCACATCTACCTCTGTGATAACCTCAGTTTATGGAAACA CAAACTCTTCTGTCCAGTCACAGACCTCTGTAATCAGCACAGTGTTCACCA CCCCAGCCAACGTTTCAACTCCAGAGACAACCTTGAAGCCTAGCCTGTCAC CTGGAAATGTTTCAGACCTTTCAACCACTAGCACTAGCCTTGCAACATCTC CCACTAAACCCTATACATCATCTTCTCCTATCCTAAGTGACATCAAGGCAG AAATCAAATGTTCAGGCATCAGAGAAGTGAAATTGACTCAGGGCATCTGC CTGGAGCAAAATAAGACCTCCAGCTGTGCGGAGTTTAAGAAGGACAGGGG AGAGGGCCTGGCCCGAGTGCTGTGTGGGGAGGAGCAGGCTGATGCTGATG CTGGGGCCCAGGTATGCTCCCTGCTCCTTGCCCAGTCTGAGGTGAGGCCTC AGTGTCTACTGCTGGTCTTGGCCAACAGAACAGAAATTTCCAGCAAACTCC AACTTATGAAAAAAGCACCAATCTGACCTGAAAAAGCTGGGGATCCTAGAT TTCACTGAGCAAGATGTTGCAAGCCACCAGAGCTATTCCCAAAAGACCCTG ATTGCACTGGTCACCTCGGGAGCCCTGCTGGCTGTCTTGGGCATCACTGGC TATTTCCTGATGAATCGCCGCAGCTGGAGCCCCACAGGAGAAAGGCTGGA GCTGGAACCCTGA
[0058] The use of the spliced CD34 gene makes it possible to select human stem cells that have integrated the exogenous nucleic acid without having signal transduction activity. In a particularly advantageous embodiment, the spliced CD34 selection marker gene is operably linked to a nucleic acid of sequence SEQ ID No. 6 encoding peptide 2A.
[0059] SEP ID No. 6 (peptide 2A): AGAGCCGAGGGCAGGGGAAGTCTTCTAA-CATGCGGGGACGTGGAGGAAAATCCCGGGCCC
[0060] The spliced CD34 selection marker gene is operably linked to a nucleic acid encoding peptide 2A and is represented by the nucleic acid sequence SEQ ID No.7.
[0061] SEP ID No, 7 (CD34 spliced selection marker gene - peptide 2A): AGAGCCGAGGGCAGGGGAAGTCTTCTAACATGCGGGGACGTGGAGGAAAA TCCCGGGCCCATGCTGGTCCGCAGGGGCGCGCGCGCAGGGCCCAGGATGC CGCGGGGCTGGACCGCGCTTTGCTTGCTGAGTTTGCTGCCTTCTGGGTTCAT GAGTCTTGACAACAACGGTACTGCTACCCCAGAGTTACCTACCCAGGGAAC ATTTTCAAATGTTTCTACAAATGTATCCTACCAAGAAACTACAACACCTAG TACCCTTGGAAGTACCAGCCTGCACCCTGTGTCTCAACATGGCAATGAGGC CACAACAAACATCACAGAAACGACAGTCAAATTCACATCTACCTCTGTGAT AACCTCAGTTTATGGAAACACAAACTCTTCTGTCCAGTCACAGACCTCTGT AATCAGCACAGTGTTCACCACCCCAGCCAACGTTTCAACTCCAGAGACAAC CTTGAAGCCTAGCCTGTCACCTGGAAATGTTTCAGACCTTTCAACCACTAG CACTAGCCTTGCAACATCTCCCACTAAACCCTATACATCATCTTCTCCTATC CTAAGTGACATCAAGGCAGAAATCAAATGTTCAGGCATCAGAGAAGTGAA ATTGACTCAGGGCATCTGCCTGGAGCAAAATAAGACCTCCAGCTGTGCGGA GTTTAAGAAGGACAGGGGAGAGGGCCTGGCCCGAGTGCTGTGTGGGGAGG AGCAGGCTGATGCTGATGCTGGGGCCCAGGTATGCTCCCTGCTCCTTGCCC AGTCTGAGGTGAGGCCTCAGTGTCTACTGCTGGTCTTGGCCAACAGAACAG AAATTTCCAGCAAACTCCAACTTATGAAAAAGCACCAATCTGACCTGAAAA AGCTGGGGATCCTAGATTTCACTGAGCAAGATGTTGCAAGCCACCAGAGCT ATTCCCAAAAGACCCTGATTGCACTGGTCACCTCGGGAGCCCTGCTGGCTG TCTTGGGCATCACTGGCTATTTCCTGATGAATCGCCGCAGCTGGAGCCCCA CAGGAGAAAGGCTGGAGCTGGAACCCTGA
[0062] Another subject of the invention relates to an expression vector, for example a viral vector, comprising the exogenous nucleic acid as defined above.
[0063] For the purposes of the present invention, the term "vector" designates a polynucleotide sequence containing the exogenous nucleic acid as defined above and control sequences in functional linkage, such that human stem cells transformed with these sequences are capable of producing the encoded proteins, in particular the fusion protein comprising a mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof and an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof.
[0064] In a particular embodiment, the human stem cell was obtained by retroviral transduction with a viral vector comprising the exogenous nucleic acid.
[0065] The vector generally comprises a promoter, translation initiation and termination signals, as well as appropriate transcriptional regulatory regions. In a particularly advantageous embodiment of the invention, the vector comprises a nucleic acid of SEQ ID No. 8. comprising: - the exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1 or a variant or fragment thereof and an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof as defined above, and - the selectable marker gene functionally linked to a nucleic acid coding for the 2A peptide as previously defined.
[0066] SEQ ID No. 8 (vectorized nucleic acid) : ATGGAACT- CAGCGTCCTCCTCTTCCTTGCACTCCTCACAGGACTCCTTGCTACTCCTGGTT CAGCGCCACCCTAACACCCATGACCGCCTCCCACCAGGGCCCCGCCCTCTG CCCCTTTTGGGAAACCTTCTGCAGATGGATAGAAGGCCTACTCAAATCC TTTCTGAGGTTCCGAGAGAAATCCGATCGAGCCTT CCGAGGCCCGTGGTCATGCTGTGTGGAGTAGAGGCCATACGGGAGGCCCTT GTGGACAAGGCTGAGGCCTTCTCTGGCCGGGGAAAATCGCCATGGTCGA CCCATTCTTCCGGGGATATGGTGTGGTCTTTGCCAATGGAAACCGCTGGAA GGTGCTTCGGCGATTCTCTGTGACCACTATGAGGGACTTCGGGGGAAA GCGGAGTGTGGAGGAGCGGATTCAGGAGGAGGCTCAGTGTCTGATAGAGG AGCTTCGGAAATCCAAGGGGGCCCATGGACCCCACCTTCCTTCCAGT CCATTACCGCCAACCATCCATCCTACCTTGATTGATT CCAAGATCAAGAGTTCCTGAAGATGATGAACTTGTTCTACCAGACTTTTTC ACTCATCAGCTCTGTATTCGGCCAGCTGTTTGAGCTCTTCTCTGGCTTCTTG AAATACTTTCCTGGGGCACACAGGCAAGTTTACAAAAACCTGCAGGAAAT CAATGCTTACATTGGCCACAGTGTGGAGAAGCACCGTGAAACCCTGGACCC CAGCGCCCCCAAGGACCTCATCGACACCTACCTGCTCCACATGGAAAAAG AGAAATCCAACGCACACAGTGAATTCAGCCACCAGAACCTCAACCTCAAC ACGCTCTCGCTCTTCTTTGCTGGCACTGAGACCACCAGCACCACTCTCCGCT ACGGCTTCCTGCTCATGCTCAAATACCCTCATGTTGCAGAGAGAGTCTACA GGGAGATTGAACAGGTGATTGGCCCACATCGCCCTCCAGAGCTTCATGACC GAGCCAAAATGCCATACACAGAGGCAGTCATCTATGAGATTCAGAGATTTT CCGACCTTCTCCCCATGGGTGTGCCCCACATTGTCACCCAACACACCAGCT TCCGAGGGTACATCATCCCCAAGGACACAGAAGTATTTCTCATCCTGAGCA CTGCTCTCCATGACCCACACTACTTTGAAAAACCAGACGCCTTCAATCCTG ACCACTTTCTGGATGCCAATGGGGCACTGAAAAAGACTGAAGCTTTTATCC CCTTCTCCTTAGGGAAGCGGATTTGTCTTGGTGAAGGCATCGCCCGTGCGG AATTGTTCCTCTTCTTCACCACCATCCTCCAGAACTTCTCCATGGCCAGCCC CGTGGCCCCAGAAGACATCGATCTGACACCCCAGGAGTGTGGTTGGGGCA AAATACCCCCAACATACCAGATCCGCTTCCTGCCCCGCTCGAGCTCTACGA TTCAGACATTGACCTCCTCTGTCAGAGAGAGCAGCTTTGTGGAAAAGATGAAGAAAACGGGGAGGAACATCATCGTGTTCTACGGCTCCCAGACGGGGACT GCAGAGGAGTTTGCCAACCGCCTGTCCAAGGACGCCCACCGCTACGGGAT GCGAGGCATGTCAGCGGACCCTGAGGAGTATGACCTGGCCGACCTGAGCA GCCTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATGGCCACCTACG GTGAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGACTGGCTGCAG GAGACAGACGTGGATCTCTCTGGGGTCAAGTTCGCGGTGTTTGGTCTTGGG AACAAGACCTACGAGCACTTCAATGCCATGGGCAAGTACGTGGACAAGCG GCTGGAGCAGCTCGGCGCCCAGCGCATCTTTGAGCTGGGGTTGGGCGACG ACGATGGGAACTTGGAGGAGGACTTCATCACCTGGCGAGAGCAGTTCTGG CCGGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGCGAGGAGTCCAG CATTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGCGGCCAAGGT GTACATGGGGGAGATGGGCCGGCTGAAGAGCTACGAGAACCAGAAGCCCC CCTTTGATGCCAAGAATCCGTTCCTGGCTGCAGTCACCACCAACCGGAAGC TGAACCAGGGAACCGAGCGCCACCTCATGCACCTGGAATTGGACATCTCG GACTCCAAAATCAGGTATGAATCTGGGGACCACGTGGCTGTGTACCCAGCC AACGACTCTGCTCTCGTCAACCAGCTGGGCAAAATCCTGGGTGCCGACCTG GACGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAACAAGAAGCA CCCATTCCCGTGCCCTACGTCCTACCGCACGGCCCTCACCTACTACCTGGAC ATCACCAACCCGCCGCGTACCAACGTGCTGTACGAGCTGGCGCAGTACGCC TCGGAGCCCTCGGAGCAGGAGCTGCTGCGCAAGATGGCCTCCTCCTCCGGC GAGGGCAAGGAGCTGTACCTGAGCTGGGTGGTGGAGGCCCGGAGGCACAT CCTGGCCATCCTGCAGGACTGCCCGTCCCTGCGGCCCCCCATCGACCACCT GTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTACTCCATCGCCTCATC CTCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCGGTGGTTGTGGAGTA CGAGACCAAGGCCGGCCGCATCAACAAGGGCGTGGCCACCAACTGGCTGC GGGCCAAGGAGCCTGCCGGGGAGAACGGCGGCCGTGCGCTGGTGCCCATG TTCGTGCGCAAGTCCCAGTTCCGCCTGCCCTTCAAGGCCACCACGCCTGTC ATCATGGTGGGCCCCGGCACCGGGGTGGCACCCTTCATAGGCTTCATCCAG GAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGGTGGGGGAGACGCTGCT GTACTACGGCTGCCGCCGCTCGGATGAGGACTACCTGTACCGGGAGGAGCT GGCGCAGTTCCACAGGGACGGTGCGCTCACCCAGCTCAACGTGGCCTTCTC CCGGGAGCAGTCCCACAAGGTCTACGTCCAGCACCTGCTAAAGCAAGACC GAGAGCACCTGTGGAAGTTGATCGAAGGCGGTGCCCACATCTACGTCTGTG GGGATGCACGGAACATGGCCAGGGATGTGCAGAACACCTTCTACGACATC GTGGCTGAGCTCGGGGCCATGGAGCACGCGCAGGCGGTGGACTACATCAA GAAACTGATGACCAAGGGCCGCTACTCCCTGGACGTGTGGAGCAGAGCCG AGGGCAGGGGAAGTCTTCTAACATGCGGGGACGTGGAGGAAAATCCCGGG CCCATGCTGGTCCGCAGGGGCGCGCGCGCAGGGCCCAGGATGCCGCGGGGCTGGACCGCGCTTTGCTTGCTGAGTTTGCTGCCTTCTGGGTTCATGAGTCTT GACAACAACGGTACTGCTACCCCAGAGTTACCTACCCAGGGAACATTTTCA AATGTTTCTACAAATGTATCCTACCAAGAAACTACAACACCTAGTACCCTT GGAAGTACCAGCCTGCACCCTGTGTCTCAACATGGCAATGAGGCCACAAC AAACATCACAGAAACGACAGTCAAATTCACATCTACCTCTGTGATAACCTC AGTTTATGGAAACACAAACTCTTCTGTCCAGTCACAGACCTCTGTAATCAG CACAGTGTTCACCACCCCAGCCAACGTTTCAACTCCAGAGACAACCTTGAA GCCTAGCCTGTCACCTGGAAATGTTTCAGACCTTTCAACCACTAGCACTAG CCTTGCAACATCTCCCACTAAACCCTATACATCATCTTCTCCTATCCTAAGT GACATCAAGGCAGAAATCAAATGTTCAGGCATCAGAGAAGTGAAATTGAC TCAGGGCATCTGCCTGGAGCAAAATAAGACCTCCAGCTGTGCGGAGTTTAA GAAGGACAGGGGAGAGGGCCTGGCCCGAGTGCTGTGTGGGGAGGAGCAG GCTGATGCTGATGCTGGGGCCCAGGTATGCTCCCTGCTCCTTGCCCAGTCT GAGGTGAGGCCTCAGTGTCTACTGCTGGTCTTGGCCAACAGAACAGAAATT TCCAGCAAACTCCAACTTATGAAAAAGCACCAATCTGACCTGAAAAAGCT GGGGATCCTAGATTTCACTGAGCAAGATGTTGCAAGCCACCAGAGCTATTC CCAAAAGACCCTGATTGCACTGGTCACCTCGGGAGCCCTGCTGGCTGTCTT GGGCATCACTGGCTATTTCCTGATGAATCGCCGCAGCTGGAGCCCCACAGG AGAAAGGCTGGAGCTGGAACCCTGA
[0067] In a particular embodiment of the invention, the vector used is a lentiviral vector, advantageously the lentiviral vector pLenti-III-EFla, marketed by the company Applied Biological Materials Inc.
[0068] The vector is stably maintained in the human stem cell and may optionally possess particular signals that specify the secretion of the translated protein. These different elements are chosen and optimized by those skilled in the art depending on the host cell used. Such vectors are prepared by methods commonly used by those skilled in the art, and the resulting clones can be introduced into the appropriate human stem cell by standard methods, such as lipofection, electroporation, the use of polycationic agents, heat shock, or chemical methods.
[0069] In another particular embodiment of the invention, the exogenous nucleic acid may be introduced by different methods into one of the safe harbor genes, in particular using transcription activator-like effector nucleation (TALEN) techniques, grouped into clustered regularly interspaced short palindromic repeats (CRISPR / Cas9) or zinc finger nucleases (ZFN) techniques. Advantageously, the integration of the exogenous nucleic acid into a safe harbor gene is achieved by using clustered regularly interspaced short palindromic repeats (CRISPR / Cas9). The use of this technology in genome editing is well described in the art. In summary, CRISPR is a microbial nuclease system involved in defense against invading phages and plasmids.CRISPR loci in microbial hosts contain a combination of CRISPR-associated genes (Cas) as well as non-coding RNA elements capable of programming the specificity of CRISPR-mediated nucleic acid (sgRNA) cleavage. Three types (I-III) of CRISPR systems have been identified across a wide range of bacterial hosts. A key feature of each CRISPR locus is the presence of an array of repetitive sequences (direct repeats) interspersed with short stretches of non-repetitive sequences (spacers). The non-coding CRISPR template is transcribed and cleaved within direct repeats into short rcRNAs containing individual spacer sequences, which direct Cas nucleases to the target site (protospacer). Type II CRISPR is one of the best-characterized systems and achieves a targeted double-stranded DNA break in four sequential steps.First, two non-coding RNAs, the pre-tRNA template and the tracrRNA, are transcribed from the CRISPR locus. Second, the tracrRNA hybridizes to the repeat regions of the pre-tRNA and mediates the processing of the pre-tRNA into mature rRNAs containing individual spacer sequences. Third, the mature tRNA:tracrRNA complex directs Cas9 to the target DNA via Watson-Crick base pairing between the spacer located on the rRNA and the pro- . tospacer located on the target DNA, next to the protospracer adjacent motif (PAM), an additional requirement for target recognition. Finally, Cas9 mediates the cleavage of the target DNA to create a double-strand break in the pro-tospacer. Cas9 is therefore the characteristic protein of the type II CRISPR-Cas system and a large monomeric DNA nuclease guided to a target DNA sequence adjacent to the protospacer adjacent motif (PAM) sequence motif by a complex of two non-coding RNAs: CRIPSR RNA (rRNA) and trans-activating rRNA (tracrRNA). The Cas9 protein contains two nuclease domains homologous to the RuvC and HNH nucleases. The HNH nuclease domain cuts the complementary DNA strand while the RuvC-like domain cuts the non-complementary strand and, therefore, a blunt cut is introduced into the target DNA.Heterologous expression of Cas9 with sgRNA can introduce site-specific double-strand breaks (DSBs) into the genomic DNA of living cells of various organisms. For applications in eukaryotic organisms, codon-optimized versions of Cas9, which originates from the bacterium Streptococcus pyogenes, have been used. Single-guide RNA (sgRNA) is the second component of the CRISPR / Cas system that forms a complex with the Cas9 nuclease. sgRNA is a synthetic RNA chimera created by the fusion of crRNA and tracrRNA. The sgRNA guide sequence located at the 5' end confers specificity to the DNA target. Therefore, by modifying the guide sequence, it is possible to create sgRNAs with different target specificities. The canonical length of the guide sequence is 20 bp. Cas9 expression vectors for use in the methods of the invention may be constructed as described in the art.
[0070] Another subject of the invention relates to the genetically modified human stem cell as defined above for its use as a medicament. In particular, the present invention relates to the genetically modified human stem cell as defined above for its use in the prevention and / or treatment of cancer and / or cancer recurrences and / or associated metastases.
[0071] Advantageously, the cancer is a cancer chosen from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as lip cancer, oral cavity cancer, oropharyngeal cancer and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, adrenal gland cancer and extra-digestive and pulmonary neuroendocrine tumors; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural cancer and lung cancer; digestive cancers, such as esophageal cancer, stomach cancer, small intestine cancer, colon cancer and rectal and / or anal canal cancer; genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, vaginal cancer and vulvar cancer; urinary cancers, such as kidney cancer and bladder cancer; sarcomas, such as soft tissue sarcoma, gastrointestinal stromal tumors (GIST) and bone sarcoma; skin cancers, such as melanoma; hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, but not limited to.
[0072] Advantageously, the invention relates to the genetically modified human stem cell as defined above for its use in the prevention and / or treatment of solid tumors, and in particular hepatocellular carcinomas, and / or cancer recurrences and / or associated metastases.
[0073] According to a particularly advantageous embodiment of the invention, the genetically modified human stem cell according to the invention is particularly useful for preventing and / or treating cancer and / or cancer recurrences and / or associated metastases.
[0074] According to a particularly advantageous embodiment of the invention, the genetically modified human stem cell according to the invention is particularly useful for preventing and / or treating solid tumors and / or cancer recurrences and / or associated metastases.
[0075] According to a particularly advantageous embodiment of the invention, the genetically modified human stem cell according to the invention is particularly useful for preventing and / or treating cancer and / or cancer recurrences and / or associated metastases chosen from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as lip cancer, oral cavity cancer, oropharyngeal cancer and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, adrenal gland cancer and extradigestive and pulmonary neuroendocrine tumors; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural cancer and lung cancer;Digestive cancers, such as esophageal cancer, stomach cancer, small intestine cancer, colon cancer, and rectal and / or anal canal cancer; Genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, vaginal cancer, and vulvar cancer; Urinary cancers, such as kidney cancer and bladder cancer; Sarcomas, such as soft tissue sarcoma, gastrointestinal stromal tumors (GIST), and bone sarcoma; Skin cancers, such as melanoma; Hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, but the list is not exhaustive.
[0076] According to a particularly advantageous embodiment of the invention, the genetically modified human stem cell according to the invention is particularly useful for preventing and / or treating hepatocellular carcinomas and / or associated metastases.
[0077] Another aspect of the invention relates to a method for selecting genetically modified stem cells as defined above, characterized in that it comprises the steps of: a) transduction of human stem cells with a viral vector comprising the exogenous nucleic acid, b) culturing the human stem cells from step a) in a predefined culture medium, and c) selection of genetically modified human stem cells expressing the selection marker gene on their membrane surface.
[0078] In a particular embodiment of the invention, the culture medium used is a medium specific to human stem cells, such as Mesenchymal Stem Cell Growth Medium 2, marketed by Promocell (Product reference: C28009).
[0079] Advantageously, the culture medium used comprises 50% of medium having been in contact with the non-transduced human stem cells for 24 hours and 50% of the same fresh medium.
[0080] In a particular embodiment, the selection marker gene is the spliced CD34 gene. Advantageously, the selection of the genetically modified human stem cells expressing the selection marker gene on their membrane surface is carried out by flow cytometry, in particular by means of the BD-FACS ARIAIII™ apparatus using anti-CD34 antibodies coupled to the fluorochrome “brilliant violet 421” (Brilliant Violet 421™) anti-human CD34 (Product reference: 343609 at Biolegend).
[0081] Another subject of the invention relates to a pharmaceutical composition comprising the genetically modified human stem cell according to the invention as active ingredient and at least one pharmaceutically acceptable excipient. In a particular embodiment of the invention, the pharmaceutical composition according to the invention comprises a therapeutically effective amount of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient.
[0082] According to a particularly advantageous embodiment of the invention, the pharmaceutical composition comprising a therapeutically effective quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above is particularly particularly useful in preventing and / or treating cancer and / or cancer recurrences and / or associated metastases.
[0083] Advantageously, the pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above is administered to a patient suffering or suspected of suffering from cancer and / or recurrences of cancer and / or associated metastases.
[0084] Advantageously, the cancer is a solid tumor cancer. For the purposes of the present invention, the term “solid tumor” means a carcinoma or a sarcoma. In a particular embodiment of the invention, the cancer is a cancer chosen from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as lip cancer, oral cavity cancer, oropharyngeal cancer and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, adrenal gland cancer and extra-digestive and pulmonary neuroendocrine tumors; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural cancer and lung cancer;Digestive cancers, such as esophageal cancer, stomach cancer, small intestine cancer, colon cancer, and rectal and / or anal canal cancer; Genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, vaginal cancer, and vulvar cancer; Urinary cancers, such as kidney cancer and bladder cancer; Sarcomas, such as soft tissue sarcoma, gastrointestinal stromal tumors (GIST), and bone sarcoma; Skin cancers, such as melanoma; Hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, but the list is not exhaustive.
[0085] According to a particularly advantageous embodiment of the invention, the pharmaceutical composition comprising a therapeutically effective quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above is particularly useful for preventing and / or treating solid tumors, and in particular hepatocellular carcinomas, and / or recurrences of cancer and / or associated metastases.
[0086] Advantageously, the pharmaceutical composition comprising a therapeutically effective quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above is administered to a patient suffering or suspected of suffering from solid tumors, and in particular from hepatocellular carcinomas, and / or from cancer recurrences. and / or associated metastases.
[0087] In one embodiment, the patient may be a human being, male or female, regardless of age. In another embodiment, the patient may be a non-human animal, advantageously a non-human mammal, for example a dog, a cat, a mouse, a rat, a hamster, a rabbit, a chinchilla, a horse, a cow, a pig, a sheep, a goat or a primate.
[0088] For the purposes of the present invention, the terms "therapeutically effective" or "effective amount to treat" or "pharmaceutically effective" designate the quantity of genetically modified human stem cells necessary to inhibit or reverse a disease, advantageously a cancer, and in particular to treat solid tumors and in particular hepatocellular carcinomas, and / or associated metastases. The determination of a therapeutically effective amount depends specifically on factors such as the toxicity and efficacy of the drug. These factors will differ depending on other factors such as activity, relative bioavailability, body weight of the patient, severity of undesirable side effects and preferred mode of administration. Toxicity can be determined using methods well known in the art. The same is true for efficacy.A pharmaceutically effective amount is, therefore, an amount that is considered by the clinician to be toxicologically tolerable, yet effective.
[0089] The dosage may be adjusted appropriately to achieve desired local or systemic, particularly trans-arterial, drug (e.g., genetically modified human stem cell) levels, depending on the route of administration. In the event that the response in a patient is insufficient at such doses, even higher doses (or more effective doses by a different, more localized route of administration) may be used as patient tolerance permits. Multiple injections approximately one week apart may also be used to achieve appropriate levels of toxic metabolites formed to cause tumor cell death and the initiation of an anti-tumor immune response. “Dose” and “dosage” are used interchangeably herein.
[0090] The injection frequency is linked to the half-life of the genetically modified human stem cells.
[0091] In an advantageous embodiment, the pharmaceutical composition according to the invention is administered to the patient at a rate of one administration per week for at least four weeks. Advantageously, the pharmaceutical composition according to the invention is administered to the patient at a rate of two administrations, advantageously three administrations, advantageously four administrations, advantageously five administrations, advantageously six administrations, advantageously preferably seven administrations per week. Advantageously, the pharmaceutical composition according to the invention is administered to the patient for at least four weeks, advantageously at least five weeks, advantageously at least six weeks, advantageously at least seven weeks, advantageously at least eight weeks, advantageously at least nine weeks, advantageously at least ten weeks.
[0092] In an advantageous embodiment, the pharmaceutical composition according to the invention further comprises at least one second active ingredient. In a particularly advantageous embodiment of the invention, the at least one second active ingredient can interact synergistically with the genetically modified human stem cells according to the invention.
[0093] Advantageously, the second active ingredient is an anti-cancer agent. Examples of a second active ingredient include cytostatic agents, cytotoxic agents, cytoprotective agents, growth inhibitory agents, toxins, and combinations thereof. Examples of anti-cancer agents that can be used in tumor therapy with the genetically modified human stem cells of the invention include cyclophosphamide (CAS number 50-18-0, also known as cyclophosphane, and the trademarks Endoxan®, Neosar®, Procytox®, and Revimmune®), AQ4N (1, 4).-bis-{[2-(dimethylamino-N-oxide)ethyl]amino]5,8-dihydroxyanthracene-9,10-dione, also known as banoxantrone®), ifosfamide (CAS number 3778-73-2), bezyloxyresorufin, 7-Ethoxy-4-trifluoromethyl-coumarin (EFC), Bupropion, thiotepa (, N'N'-triethylenethiophosphoramide, CAS number 52-24-4), my-tomycin C (CAS number 50-0-07), tirapazamine (SR-4233, CAS number 27314-97-2). ). Examples of cytoprotective agents include mesna, also known under the trademark Uromitexian®. Advantageously, the second active ingredient may comprise a combination of anticancer agents, such as those listed above. In a particularly advantageous embodiment, the second active ingredient is a combination of an anticancer agent and a cytoprotective agent. In a particularly advantageous embodiment, the second active ingredient is a combination of cyclophosphamide and mesna.
[0094] In a particular embodiment, the pharmaceutical composition according to the invention comprises genetically modified human stem cells as defined above as active ingredient and cyclophosphamide as second active ingredient.
[0095] In a particular embodiment, the pharmaceutical composition according to the invention comprises genetically modified human stem cells as defined above as active ingredient and mesna as second active ingredient.
[0096] In a particular embodiment according to the invention, the second active ingredient may be in the form of granules, powders, tablets, coated tablets, (micro)capsules, syrups, emulsions, suspensions or prolonged-release preparations. In another particular embodiment according to the invention, the second active ingredient may be in a form that can be administered parenterally.
[0097] In a particular embodiment, the pharmaceutical composition according to the invention comprises genetically modified human stem cells as defined above as active ingredient and cyclophosphamide as second active ingredient and at least one pharmaceutically acceptable excipient.
[0098] In a particular embodiment, the pharmaceutical composition according to the invention comprises genetically modified human stem cells as defined above as active ingredient and cyclophosphamide and mesna as second active ingredient and at least one pharmaceutically acceptable excipient.
[0099] In an advantageous embodiment of the invention, when the pharmaceutical composition comprises a second active ingredient, the pharmaceutical composition is suitable for simultaneous administration or sequential administration of the genetically modified human stem cells and the second active ingredient.
[0100] For the purposes of the present invention, the term "simultaneous administration" means an administration of the genetically modified human stem cells and the second active ingredient at the same time, at the same time, to a patient in therapeutically effective amounts to enable the synergistic effect of the pharmaceutical composition. This does not mean, however, that the genetically modified human stem cells and the second active ingredient are necessarily administered in the form of a mixture; they can in fact be administered simultaneously but separately, in the form of distinct compositions.
[0101] By "present in two distinct compositions" is meant that the genetically modified human stem cells and the second active ingredient are physically separated. They are then implemented, administered separately in therapeutically effective amounts to allow the synergistic effect of the pharmaceutical composition, without prior mixing, in several (at least two) dosage forms (for example two distinct compositions).
[0102] In another particular embodiment of the invention, the genetically modified human stem cells and the second active ingredient may be present in the same composition in therapeutically effective amounts to enable the synergistic effect of the pharmaceutical composition. For the purposes of the present invention, the term "present in the same composition" means the combination physical properties of the genetically modified human stem cells and the second active ingredient. The genetically modified human stem cells and the second active ingredient are then necessarily administered simultaneously since they are administered together, in the form of a mixture, in the same dosage form (for example in a single composition containing the genetically modified human stem cells and the anti-cancer agent) and in therapeutically effective amounts to enable the synergistic effect of the pharmaceutical composition.
[0103] For the purposes of the present invention, the expression "sequential administration" means that the genetically modified human stem cells and the second active ingredient are administered in therapeutically effective amounts to enable the synergistic effect of the pharmaceutical composition, not simultaneously but separately in time, one after the other. The terms "precede" or "preceding" and "follow" or "following" then apply. The term "precede" or "preceding" is used when a compound of the pharmaceutical composition according to the invention is administered a few minutes or several hours, or even several days before the administration of the other compound(s) of the pharmaceutical composition.Conversely, the term "follow" or "next" is used when a compound of the pharmaceutical composition is administered a few minutes or several hours, or even several days after the administration of the other compound(s) of the pharmaceutical composition. In a particularly advantageous embodiment of the invention, the genetically modified human stem cells are administered a few days before the second active ingredient.
[0104] In an advantageous embodiment of the invention, when the pharmaceutical composition comprises a second active ingredient, the pharmaceutical composition is suitable for sequential administration of the genetically modified human stem cells and the second active ingredient. Advantageously, the second active ingredient is cyclophosphamide used alone or in combination with mesna.
[0105] In a particular embodiment of the invention, the genetically modified human stem cells are administered to the patient, then two to three days after the administration of the genetically modified human stem cells, cyclophosphamide, alone or in combination with mesna, is administered to this same patient, and this at a rate of two administrations of genetically modified human stem cells and cyclophosphamide, alone or in combination with mesna, per week for at least four weeks, advantageously at least five weeks, advantageously at least six weeks, advantageously at least seven weeks, advantageously at least eight weeks, advantageously at least nine weeks, advantageously at least ten weeks.
[0106] Depending on the intended mode of administration in vivo, the pharmaceutical composition used may be in solid, semi-solid or liquid dosage form such as tablets, pills, powders, capsules, gels, ointments, liquids, suspensions or the like. Preferably, the pharmaceutical compositions are administered in unit dosage forms suitable for single administration of precise dosage amounts. The pharmaceutical compositions may also comprise, depending on the desired formulation, at least one pharmaceutically acceptable carrier or diluent, which are defined as aqueous-based vehicles commonly used for formulations intended for human administration. The diluent is chosen so as not to affect the biological activity of the active compounds present in the pharmaceutical composition of the invention. Examples of such diluents are distilled water, saline, Ringer's solution, dextrose solution and Hank's solution.Effective amounts of such a diluent or carrier are amounts effective to obtain a pharmaceutically acceptable formulation in terms of solubility of the components, biological activity, etc. In certain embodiments, the pharmaceutical compositions provided herein are sterile.
[0107] Suitable liquid pharmaceutical preparation forms may include, in particular, aqueous or saline solutions, wherein said aqueous or saline solutions may be microencapsulated, notched, coated on microscopic gold particles, contained in liposomes.
[0108] Administration of the pharmaceutical composition or the genetically modified human stem cell according to the present invention may be by any route of administration, including oral, topical, parenteral (also referred to as systemic or general), intramuscular, intranasal, sublingual, intratracheal, inhalation, ocular, vaginal and rectal. Intracapsular, intravenous, transarterial, intraarterial and intraperitoneal routes of administration may also be used. Those skilled in the art will be able to choose the appropriate route of administration depending on the disorder to be treated.
[0109] Advantageously, the pharmaceutical composition or the genetically modified human stem cell according to the present invention can be administered to a subject by parenteral route, advantageously by trans-arterial route.
[0110] The compositions, when desirable for systemic administration, may be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion. The formulations for injection may be presented in unit dosage form, for example, in ampoules or in multiple-dose containers, with an added preservative. The compositions may take forms such as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain preservatives. mulation such as suspending agents, stabilizers and / or dispersants.
[0111] Pharmaceutical formulations for parenteral administration comprise aqueous solutions of the active compositions in water-soluble form. In addition, suspensions of the active compositions may be prepared as suitable oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. The aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compositions to enable the preparation of highly concentrated solutions.Alternatively, the active compositions may be in the form of powders to provide a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0112] Even more advantageously, the pharmaceutical composition or the genetically modified human stem cell according to the present invention can be administered to a patient by trans-arterial route. According to a particular embodiment of the invention, the pharmaceutical composition or the genetically modified human stem cell according to the present invention are in a form suitable for its administration by trans-arterial route.
[0113] In a particularly advantageous embodiment, the genetically modified human stem cells according to the present invention represent from 0.5 to 98% by weight, or even more, of the total weight of the pharmaceutical composition considered.
[0114] In a particularly advantageous embodiment of the present invention, the pharmaceutical composition according to the invention comprises only the genetically modified human stem cells as defined above, as the sole active ingredient.
[0115] Another subject of the invention relates to a method for the preventive treatment of cancer and / or associated metastases, comprising the administration to the patient of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically effective quantity of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above.
[0116] For the purposes of the present invention, the term "prevention" or "prophylaxis" or "preventive treatment" or "prophylactic treatment" includes a treatment leading to the prevention of a disease as well as a treatment reducing and / or delaying the incidence of a disease or the risk of occurrence of the disease.
[0117] According to the present invention, the genetically modified human stem cell is particularly effective in preventing recurrences and the appearance of new metastases, by provoking a strong anti-tumor immune response, thus inducing a protective effect against recurrences and metastases.
[0118] In a particularly advantageous embodiment, the present invention provides a method for the preventive treatment of cancer and / or cancer recurrences and / or associated metastases, comprising administering to the patient genetically modified human stem cells or a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above and a second active ingredient as defined above.
[0119] Advantageously, the cancer is a solid tumor cancer. For the purposes of the present invention, the term "solid tumor" means a carcinoma or a sarcoma. In a particular embodiment of the invention, the cancer is a cancer chosen from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as lip cancer, oral cavity cancer, oropharyngeal cancer and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, adrenal gland cancer and extra-digestive and pulmonary neuroendocrine tumors; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural cancer and lung cancer;Digestive cancers, such as esophageal cancer, stomach cancer, small bowel cancer, colon cancer, and rectal and / or anal canal cancer; Genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, vaginal cancer, and vulvar cancer; Urinary cancers, such as kidney cancer and bladder cancer; Sarcomas, such as soft tissue sarcoma, gastrointestinal stromal tumors (GIST), and bone sarcoma; Skin cancers, such as melanoma; Hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, but the list is not exhaustive. Advantageously, the cancer is a solid tumor, in particular a hepatocellular carcinoma, and / or cancer recurrences and / or associated metastases.
[0120] In a particularly advantageous embodiment, the present invention relates to a method for the preventive treatment of hepatocellular carcinoma, comprising administering to the patient genetically modified human stem cells or a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above.
[0121] In a particularly advantageous embodiment, the present invention relates to a method for the preventive treatment of hepatocellular carcinoma, comprising the administration to the patient of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above and a second active ingredient as defined above.
[0122] In a particularly advantageous embodiment, the present invention relates to the use of a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as an active ingredient in the manufacture of a medicament intended for the prevention of cancer and / or cancer recurrences and / or associated metastases.
[0123] Advantageously, the cancer is a solid tumor cancer. For the purposes of the present invention, the term "solid tumor" means a carcinoma or a sarcoma. In a particular embodiment of the invention, the cancer is a cancer chosen from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as lip cancer, oral cavity cancer, oropharyngeal cancer and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, adrenal gland cancer and extra-digestive and pulmonary neuroendocrine tumors; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural cancer and lung cancer;Digestive cancers, such as esophageal cancer, stomach cancer, small bowel cancer, colon cancer, and rectal and / or anal canal cancer; Genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, vaginal cancer, and vulvar cancer; Urinary cancers, such as kidney cancer and bladder cancer; Sarcomas, such as soft tissue sarcoma, gastrointestinal stromal tumors (GIST), and bone sarcoma; Skin cancers, such as melanoma; Hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, but the list is not exhaustive. Advantageously, the cancer is a solid tumor, in particular a hepatocellular carcinoma and / or associated metastases.
[0124] In a particularly advantageous embodiment, the present invention relates to the use of a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as an active ingredient in the manufacture of a medicament intended for the prevention of solid tumors, and in particular hepatocellular carcinomas, and / or cancer recurrences and / or associated metastases.
[0125] Another subject of the invention relates to a method for the curative treatment of cancer and / or associated metastases in patients requiring administration, comprising the administration to said patients of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above.
[0126] For the purposes of the present invention, the term "treatment" or "curative treatment" is defined as a treatment leading to a cure or a treatment which alleviates, improves and / or eliminates, reduces and / or stabilizes the symptoms of a disease or the suffering it causes.
[0127] Another subject of the invention relates to a method for the curative treatment of cancer and / or cancer recurrences and / or associated metastases in patients requiring administration, comprising the administration to said patients of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above and a second active ingredient as defined above.
[0128] Advantageously, the cancer is a solid tumor cancer. For the purposes of the present invention, the term "solid tumor" means a carcinoma or a sarcoma. In a particular embodiment of the invention, the cancer is a cancer chosen from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as lip cancer, oral cavity cancer, oropharyngeal cancer and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, adrenal gland cancer and extra-digestive and pulmonary neuroendocrine tumors; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural cancer and lung cancer;Digestive cancers, such as esophageal cancer, stomach cancer, small bowel cancer, colon cancer, and rectal and / or anal canal cancer; Genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, vaginal cancer, and vulvar cancer; Urinary cancers, such as kidney cancer and bladder cancer; Sarcomas, such as soft tissue sarcoma, gastrointestinal stromal tumors (GIST), and bone sarcoma; Skin cancers, such as melanoma, hepatocellular carcinoma; biliary, such as hepatocellular carcinoma and cholangiocarcinoma, the list being not exhaustive. Advantageously, the cancer is a solid tumor, in particular hepatocellular carcinoma and / or associated metastases.
[0129] Another subject of the invention relates to a method for the curative treatment of a solid tumor, advantageously hepatocellular carcinomas and / or associated metastases, in patients requiring administration, comprising the administration to said patients of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above.
[0130] Another subject of the invention relates to a method for the curative treatment of a solid tumor, advantageously hepatocellular carcinomas and / or associated metastases, in patients requiring administration, comprising the administration to said patients of genetically modified human stem cells or of a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as active ingredient and at least one pharmaceutically acceptable excipient as defined above and a second active ingredient as defined above.In a particularly advantageous embodiment, the present invention relates to the use of a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as an active ingredient in the manufacture of a medicament intended for the treatment of cancer and / or associated metastases.
[0131] Advantageously, the cancer is a solid tumor cancer. For the purposes of the present invention, the term "solid tumor" means a carcinoma or a sarcoma. In a particular embodiment of the invention, the cancer is a cancer chosen from: cancers affecting the central nervous system, such as astrocytomas and gliomas; cancers of the upper aerodigestive tract (ENT), such as lip cancer, oral cavity cancer, oropharyngeal cancer and nasopharyngeal cancer; cancers of the endocrine glands, such as thyroid cancer, adrenal gland cancer and extra-digestive and pulmonary neuroendocrine tumors; cancers of the exocrine glands, such as breast cancer and pancreatic cancer; cancers affecting the thorax, such as pleural cancer and lung cancer;digestive cancers, such as esophageal cancer, stomach cancer, small intestine cancer, colon cancer, and rectal and / or anal canal cancer; genital cancers, such as prostate cancer, cervical cancer, endometrial cancer, vaginal cancer, and vulvar cancer; cancers; urinary tract cancers, such as kidney cancer and bladder cancer; sarcomas, such as soft tissue sarcoma, gastrointestinal stromal tumors (GIST) and bone sarcoma; skin cancers, such as melanoma; hepatobiliary cancers, such as hepatocellular carcinoma and cholangiocarcinoma, but the list is not exhaustive.
[0132] In a particularly advantageous embodiment, the present invention relates to the use of a pharmaceutical composition comprising a therapeutically effective amount of genetically modified human stem cells as an active ingredient in the manufacture of a medicament intended for the treatment of solid tumors, and in particular hepatocellular carcinomas, and / or associated metastases.
Claims
Claims
1. A genetically modified human stem cell, wherein said human stem cell comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 protein (CYP2B6*) of SEQ ID No. 1; and an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2; operably linked to a promoter, said exogenous nucleic acid having been inserted into one of the safe harbor genes of said human stem cell and characterized in that said genetically modified human stem cell is not an embryonic human stem cell.
2. The genetically modified human stem cell of claim 1, wherein said human stem cell is selected from mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs) and induced mesenchymal stem cells (iMSCs).
3. Genetically modified human stem cell according to claim 1 or 2, wherein the safe harbor gene selected from: the AAVS1 site of chromosome 19, the CCR5 site of chromosome 3, the hROSA26 site of chromosome 3, the site 323 of chromosome 1, the site 325 of chromosome 8, the site 289 of chromosome 1, the site 227 of chromosome 1, the site 229 of chromosome 2, the site 253 of chromosome 2, the site 255 of chromosome 5, the site 257 of chromosome 7, the site 259 of chromosome 14, the site 261 of chromosome 17, the site 263 of chromosome X, the site 317 of chromosome 2, the site 303 of chromosome 2, the site 331 of chromosome 3, the site 283 of chromosome 4, the site 231 of chromosome 4, site 315 of chromosome 5, site 327 of chromosome 5, site 305 of chromosome 5, site 307 of chromosome 16, site 309 of chromosome 20, site 285 of chromosome 6, site 233 of chromosome 6, site 311 of chromosome 6, site 299 of chromosome 6,site 301 of chromosome 7, site 293 of chromosome 8, site 319 of chromosome 11, site 333 of chromosome 12, site 295 of chromosome 12, site 329 of chromosome 12, site 297 of chromosome 17, site 291 of chromosome 22, site 313 of chromosome X and site 321 of, X chromosome.
4. A genetically modified human stem cell according to any one of claims 1 to 3, wherein the promoter is a constitutive promoter, preferably the EF1-a promoter.
5. A genetically modified human stem cell according to any one of claims 1 to 4, wherein said exogenous nucleic acid further comprises a selection marker gene.
6. A genetically modified human stem cell according to any one of claims 1 to 5, wherein the human stem cell was obtained by retroviral transduction with a viral vector comprising the exogenous nucleic acid.
7. Method for obtaining and selecting genetically modified stem cells according to any one of claims 1 to 6, characterized in that it comprises the steps of: a) transduction of the human stem cells with a viral vector comprising the exogenous nucleic acid, said nucleic acid comprises a selection marker gene, b) culturing the human stem cells in a predefined culture medium, c) selection of the genetically modified human stem cells expressing the selection marker gene on their membrane surface.
8. Pharmaceutical composition comprising the genetically modified human stem cell according to any one of claims 1 to 6, as active ingredient and at least one pharmaceutically acceptable excipient.
9. A pharmaceutical composition according to claim 8, further comprising at least one second active ingredient.
10. A pharmaceutical composition according to claim 9, wherein the second active ingredient is an anti-cancer agent.
11. Pharmaceutical composition according to any one of claims 8 to 10, characterized in that it is in a form suitable for its administration by trans-arterial route.
12. Pharmaceutical composition according to any one of claims 8 to 11 for use in the prevention and / or treatment of cancer and / or cancer recurrences and / or associated metastases, preferably solid tumors, preferably hepatocellular carcinomas, and / or associated metastases.
